RxDoctor Payments Data

James Hollier, MD

Gastroenterology · Lafayette, LANPI 1922461367

Payments from drug & device makers

$4,405in general payments, 2019–2025

Across 228 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$800
  • Olympus Corporation Of The Americas$672
  • Takeda Pharmaceuticals U.S.A., Inc.$215
  • Bristol Myers Squibb$201
  • Gilead$179
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$51112%
  • Food & beverage$3,88588%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,405 in reported general payments places this provider in the 55th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$173,456
Medicare patients
545
Services billed
1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$298,323
LinzessLinaclotide22$11,544
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates146$9,734
Pantoprazole Sodium425$5,374
ClenpiqSod Picosulf/Mag Ox/Citric Ac25$4,223
Mesalamine19$3,774
Esomeprazole Magnesium65$3,011
Omeprazole102$1,819
Sucralfate36$1,536
Colesevelam Hcl16$1,323
Famotidine37$524
Rabeprazole Sodium12$453
Lansoprazole13$398
Dicyclomine Hcl57$296
Spironolactone14$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$800$298,32312 claims
AbbVieLinzess$1,258$11,54422 claims
Ferring Pharmaceuticals Inc.Clenpiq$72$4,22325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →